GB8530308D0 - Antibodies - Google Patents

Antibodies

Info

Publication number
GB8530308D0
GB8530308D0 GB858530308A GB8530308A GB8530308D0 GB 8530308 D0 GB8530308 D0 GB 8530308D0 GB 858530308 A GB858530308 A GB 858530308A GB 8530308 A GB8530308 A GB 8530308A GB 8530308 D0 GB8530308 D0 GB 8530308D0
Authority
GB
United Kingdom
Prior art keywords
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB858530308A
Other versions
GB2168998B (en
GB2168998A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of GB8530308D0 publication Critical patent/GB8530308D0/en
Publication of GB2168998A publication Critical patent/GB2168998A/en
Application granted granted Critical
Publication of GB2168998B publication Critical patent/GB2168998B/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
GB08530308A 1982-04-12 1985-12-09 Antibodies having dual specificities, their preparation and uses therefor Expired GB2168998B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36778482A 1982-04-12 1982-04-12

Publications (3)

Publication Number Publication Date
GB8530308D0 true GB8530308D0 (en) 1986-01-22
GB2168998A GB2168998A (en) 1986-07-02
GB2168998B GB2168998B (en) 1987-03-04

Family

ID=23448582

Family Applications (4)

Application Number Title Priority Date Filing Date
GB08332646A Expired GB2128631B (en) 1982-04-12 1983-04-12 Antibodies having dual specificities their preparation and uses therefor
GB08530310A Expired GB2167086B (en) 1982-04-12 1985-12-09 Antibodies having dual specificities, their preparation and uses therefor
GB08530308A Expired GB2168998B (en) 1982-04-12 1985-12-09 Antibodies having dual specificities, their preparation and uses therefor
GB08530309A Expired GB2169921B (en) 1982-04-12 1985-12-09 Antibodies having dual specificities, their preparation and uses therefor

Family Applications Before (2)

Application Number Title Priority Date Filing Date
GB08332646A Expired GB2128631B (en) 1982-04-12 1983-04-12 Antibodies having dual specificities their preparation and uses therefor
GB08530310A Expired GB2167086B (en) 1982-04-12 1985-12-09 Antibodies having dual specificities, their preparation and uses therefor

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB08530309A Expired GB2169921B (en) 1982-04-12 1985-12-09 Antibodies having dual specificities, their preparation and uses therefor

Country Status (11)

Country Link
EP (1) EP0105360A4 (en)
JP (2) JPH0753119B2 (en)
AT (1) AT394577B (en)
AU (1) AU550486B2 (en)
CA (1) CA1213229A (en)
CH (1) CH672796A5 (en)
ES (7) ES521370A0 (en)
FI (1) FI834529A0 (en)
GB (4) GB2128631B (en)
IT (1) IT1219778B (en)
WO (1) WO1983003679A1 (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3177776B2 (en) * 1988-09-27 2001-06-18 武田薬品工業株式会社 Hybrid monoclonal antibodies, antibody-producing polydomas and antibody-containing drugs
US5292668A (en) * 1981-12-21 1994-03-08 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
IL70686A (en) * 1983-01-20 1988-07-31 Suntory Ltd Mutant tumor cell lines for use in the preparation of hybridomas and the hybridomas obtained therefrom
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
EP0467416A1 (en) * 1983-09-01 1992-01-22 Hybritech Incorporated Antibody compositions of therapeutic agents having an extended serum half-life
AU595159B2 (en) * 1984-04-23 1990-03-29 Boston Biomedical Research Institute Incorporated Bispecific antibody determinants
NL8501219A (en) * 1985-04-29 1986-11-17 Stichting Vrienden Van De Stic IMMUNOLOGICAL COMPLEX, ITS PREPARATION AND APPLICATION.
EP0241907A3 (en) 1986-04-14 1989-09-13 The General Hospital Corporation Heterobifunctional antibodies and method of use
US5453269A (en) * 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
FR2604092B1 (en) * 1986-09-19 1990-04-13 Immunotech Sa IMMUNOREACTIVES FOR TARGETING ANIMAL CELLS FOR VISUALIZATION OR DESTRUCTION IN VIVO
GB8626413D0 (en) * 1986-11-05 1986-12-03 Gilliland L K Antibodies
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies
US5053226A (en) * 1987-07-15 1991-10-01 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
JP2755395B2 (en) * 1987-09-23 1998-05-20 ブリストル―マイアーズ スクイブ コムパニー Antibody heteroconjugate that kills HIV-infected cells
GB2218100A (en) * 1988-03-02 1989-11-08 Erling Sundrehagen Conjugates for the detection and/or quantification of antigenic substances in body fluids
US4892824A (en) * 1988-03-15 1990-01-09 Synbiotics Corporation Fast track method for producing monoclonal bi-specific immunoglobulins
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
JPH02196799A (en) * 1988-04-08 1990-08-03 Agency Of Ind Science & Technol Complex of anti-human cancer protein
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
IT1235349B (en) * 1988-12-23 1992-06-30 Biodata Spa IMMUNOLOGICAL TEST FOR HOMOGENEOUS DETERMINATIONS
US5217713A (en) * 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
CA2006408A1 (en) * 1988-12-27 1990-06-27 Susumu Iwasa Bispecific monoclonal antibody, its production and use
WO1990012109A1 (en) * 1989-03-30 1990-10-18 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
FR2652004B1 (en) * 1989-09-21 1994-10-28 Immunotech Partners NOVEL HYDROPHILIC DERIVATIVES, APPLICATION TO DIAGNOSIS AND THERAPEUTICS, DIAGNOSTIC OR THERAPEUTIC KITS AND IMMUNOLOGICAL REAGENTS.
DE69130561T2 (en) * 1990-02-16 1999-06-24 Boston Biomedical Research Institute, Inc., Boston, Mass. Hybrid reagents with the ability to selectively release molecules into cells
TW212184B (en) * 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
US5573920A (en) * 1991-04-26 1996-11-12 Surface Active Limited Antibodies, and methods for their use
GB9316369D0 (en) * 1993-08-06 1993-09-22 Surface Active Ltd Diagnostic method
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
GB9421468D0 (en) * 1994-10-18 1994-12-07 Surface Active Ltd Biosensor
EP0937146A2 (en) * 1996-09-20 1999-08-25 The General Hospital Corporation Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin
US20020132274A1 (en) 2001-01-17 2002-09-19 Nevalainen Marja T. Diagnostic and monitorings methods for cancer
US7659241B2 (en) 2002-07-31 2010-02-09 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US7932242B2 (en) 2004-03-16 2011-04-26 Temple University - Of The Commonwealth System Of Higher Education Substituted phenoxy-and phenylthio-derivatives for treating proliferative disorders
JP2008519863A (en) 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド Auristatin having an aminobenzoic acid unit at the N-terminus
EP2511299A1 (en) 2005-04-19 2012-10-17 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
EP4026840A1 (en) 2005-07-18 2022-07-13 Seagen Inc. Beta-glucuronide-linker drug conjugates
EP2609932B1 (en) 2006-12-01 2022-02-02 Seagen Inc. Variant target binding agents and uses thereof
ZA200904482B (en) 2007-01-22 2010-09-29 Genentech Inc Polyelectrolyte precipitation and purification of antibodies
AU2009242453B2 (en) 2008-05-02 2014-12-04 Seagen Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2011133658A1 (en) 2010-04-22 2011-10-27 Boston Medical Center Corporation Compositions and methods for targeting and delivering therapeutics into cells
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
MY174813A (en) 2013-03-15 2020-05-16 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
JP6473418B2 (en) 2013-10-10 2019-02-20 幸成 加藤 Anti-podopranin antibody
CN106255513B (en) 2013-12-27 2022-01-14 酵活有限公司 Sulfonamide-containing linking systems for drug conjugates
AU2015318556C1 (en) 2014-09-17 2021-01-07 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US10618935B2 (en) 2015-11-03 2020-04-14 Industrial Technology Research Institute Antibody-drug conjugate (ADC) and method for forming the same
SG11201807827VA (en) 2016-03-25 2018-10-30 Seattle Genetics Inc Process for the preparation of pegylated drug-linkers and intermediates thereof
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
MX2019010769A (en) 2017-03-24 2019-12-11 Seattle Genetics Inc Process for the preparation of glucuronide drug-linkers and intermediates thereof.
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
CA3110096A1 (en) 2018-08-30 2020-03-05 Innovative Cellular Therapeutics CO., LTD. Chimeric antigen receptor cells for treating solid tumor
US20220409734A1 (en) 2019-05-10 2022-12-29 Yutaka Nishimoto Antibody drug conjugates
TW202138388A (en) 2019-12-30 2021-10-16 美商西根公司 Methods of treating cancer with nonfucosylated anti-cd70 antibodies
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
WO2022097117A1 (en) 2020-11-09 2022-05-12 Takeda Pharmaceutical Company Ltd. Antibody drug conjugates
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
WO2023278377A1 (en) 2021-06-29 2023-01-05 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130634A (en) * 1974-03-15 1978-12-19 University Of Illinois Foundation Method for detecting and quantifying antigens
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies

Also Published As

Publication number Publication date
FI834529A (en) 1983-12-09
CA1213229A (en) 1986-10-28
ATA901883A (en) 1991-10-15
ES527963A0 (en) 1985-02-16
ES8504461A1 (en) 1985-04-16
JPS6312276A (en) 1988-01-19
GB8530310D0 (en) 1986-01-22
GB2128631A (en) 1984-05-02
ES8607386A1 (en) 1986-05-16
ES8503441A1 (en) 1985-02-16
GB8332646D0 (en) 1984-01-11
GB2169921B (en) 1987-03-04
IT1219778B (en) 1990-05-24
WO1983003679A1 (en) 1983-10-27
ES537257A0 (en) 1986-04-01
GB2168998B (en) 1987-03-04
GB2167086B (en) 1987-03-04
ES545247A0 (en) 1986-05-16
FI834529A0 (en) 1983-12-09
JPH0753600A (en) 1995-02-28
AU550486B2 (en) 1986-03-20
GB8530309D0 (en) 1986-01-22
CH672796A5 (en) 1989-12-29
GB2169921A (en) 1986-07-23
ES521370A0 (en) 1985-04-16
ES538727A0 (en) 1986-02-01
GB2168998A (en) 1986-07-02
EP0105360A4 (en) 1986-07-08
AU1555983A (en) 1983-11-04
ES8606655A1 (en) 1986-04-01
ES8506091A1 (en) 1985-06-16
AT394577B (en) 1992-05-11
GB2128631B (en) 1987-02-25
GB2167086A (en) 1986-05-21
ES8604424A1 (en) 1986-02-01
JPH0753119B2 (en) 1995-06-07
IT8320548A0 (en) 1983-04-12
ES533931A0 (en) 1985-06-16
EP0105360A1 (en) 1984-04-18
JP2562002B2 (en) 1996-12-11
ES533930A0 (en) 1985-12-01
ES8603080A1 (en) 1985-12-01

Similar Documents

Publication Publication Date Title
GB8530308D0 (en) Antibodies
CS124683A2 (en) Zpusob zapouzdreni ucinne latky chemickeho prostredku
GB8300371D0 (en) Immunoassay
GB8316001D0 (en) Monoclonal antibodies
AR242637A1 (en) Staking-machine
IL68601A0 (en) Eye-protecting means
CS102482A1 (en) Stabilizacni zarizeni plasmoveho generatoru
CS1010682A1 (en) Samosvorny hydraulicky obvod
CA50080S (en) Bruach
CA50660S (en) Gamesboard
CA50163S (en) Skillet-oven
IE820162L (en) Manufacturing antibodies
BG46479A1 (en) Spasmalytic means
BG35837A1 (en) Antiicer means
BG35198A1 (en) Nitratereductase means
BG33766A1 (en) Insectiside means
BG33765A1 (en) Insectiside means
CS12382A1 (en) Spektrofluorometr
CS1002182A1 (en) Zpusob vyroby magneticky mekkych ocelovych plechu nebo pasu
AU88266S (en) Boardgame
AU89092S (en) Aquabike
CS129983A1 (en) Indikator brzdove polohy
CS156182A1 (en) Stabilizovany zdroj sinusoveho prudu
CS719782A1 (en) Sposob vyroby metylvinylketonu
BG34948A1 (en) Box- pallet

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Effective date: 20030411